CredoScientia - Bibliothèque

Stage III-IV thymic squamous cell carcinoma in complete pathological remission achieved with thymic cancer resection after immunotherapy combined with chemotherapeutic conversion therapy: a report of two cases from real-world data.

BACKGROUND: Thymic carcinoma, a rare malignancy in the mediastinum, currently lacks standardized treatment options. Although surgery remains a crucial component among traditional therapeutic approache…

Thérapies de Conversion

Li, D., Minervini, F., Planas, G., Okuda, K., Ozeki, N., & Zou, Y. (2024). Stage III-IV thymic squamous cell carcinoma in complete pathological remission achieved with thymic cancer resection after immunotherapy combined with chemotherapeutic conversion therapy: a report of two cases from real-world data.. Gland Surg, 13(1), 117-127. https://doi.org/10.21037/gs-23-488

29/01/2024 Lire →

Conversion practices in Aotearoa New Zealand: Developing a holistic response to spiritual abuse.

Research arising from conversion practices, also known as conversion therapy and sexual orientation and gender identity change efforts, has generally been underpinned by an emancipatory discourse that…

Trauma Psychologique Religieux Abus Spirituels et Emprise Religieuse Thérapies de Conversion

Roguski, M., & Atwool, N. (2024). Conversion practices in Aotearoa New Zealand: Developing a holistic response to spiritual abuse.. PLoS One, 19(5), e0302163. https://doi.org/10.1371/journal.pone.0302163

01/01/2024 Lire →

FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.

BACKGROUND: Hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen has demonstrated efficacy in patients with unresectable hepatocellular carcinoma (HCC). The combined targeted and immu…

Thérapies de Conversion

Lu, Y. C., Yang, Y. C., Ma, D., Wang, J. Q., Hao, F. J., Chen, X. X., & Chen, Y. J. (2024). FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.. Front Immunol, 15, 1471017. https://doi.org/10.3389/fimmu.2024.1471017

01/01/2024 Lire →

A case report of a patient with stage IIIa hepatocellular carcinoma complicated by early gastric cancer.

We report a case of patient with Stage IIIa Hepatocellular Carcinoma Complicated by Early Gastric Cancer. Although Stage IIIa liver cancer can be treated with surgery, the overall prognosis of surgery…

Thérapies de Conversion

Song, X., Cai, R., Wang, L., Ding, F., & Ni, H. (2024). A case report of a patient with stage IIIa hepatocellular carcinoma complicated by early gastric cancer.. Front Oncol, 14, 1440171. https://doi.org/10.3389/fonc.2024.1440171

01/01/2024 Lire →

Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.

The diagnosis and treatment of head and neck undifferentiated carcinoma (HNUC) present significant challenges. Herein, we present the case of a patient with advanced HNUC who underwent conversion surg…

Thérapies de Conversion

Li, J., Zhan, X., Shang, W., & Song, K. (2024). Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.. Front Immunol, 15, 1484915. https://doi.org/10.3389/fimmu.2024.1484915

01/01/2024 Lire →

Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.

BACKGROUND: LCP-Tacro [LCPT], a novel once-daily, extended-release formulation of tacrolimus, has a reduced C with comparable AUC exposure, requiring a ∼30% dose reduction in contrast to immediate-rel…

Thérapies de Conversion

Anft, M., Zgoura, P., Skrzypczyk, S., Dürr, M., Viebahn, R., Westhoff, T. H., Stervbo, U., & Babel, N. (2024). Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.. Front Transplant, 3, 1405070. https://doi.org/10.3389/frtra.2024.1405070

01/01/2024 Lire →

Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.

The combination therapy of Tislelizumab plus Lenvatinib has recently emerged as the new standard of care for unresectable hepatocellular carcinoma (HCC). This treatment has demonstrated a significant …

Thérapies de Conversion

Xie, Y., Lyu, T., Zou, Y., & Wang, J. (2024). Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.. Front Oncol, 14, 1369567. https://doi.org/10.3389/fonc.2024.1369567

01/01/2024 Lire →

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.

Hepatocellular carcinoma is a rather common malignant tumor. Most patients with hepatocellular carcinoma receive their diagnosis at an advanced stage, at which surgical resection is no longer appropri…

Thérapies de Conversion

Liu, X. L., Li, X. Z., Chu, Y. F., Liu, F., & Tian, H. (2024). Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.. Front Oncol, 14, 1280805. https://doi.org/10.3389/fonc.2024.1280805

01/01/2024 Lire →

"Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.

This is a mixed methods international survey of therapists ( = 89) belonging to Therapy First, an organization supporting the use of exploratory therapy, rather than gender affirmative therapy, with g…

Thérapies de Conversion

Jenkins, P., & Panozzo, D. (2024). "Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.. J Sex Marital Ther, 50(5), 557-582. https://doi.org/10.1080/0092623X.2024.2329761

01/01/2024 Lire →

Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report.

BACKGROUND: The synergistic effectiveness of combining immune checkpoint inhibitors with targeted therapies has shown promise in improving the conversion rate for unresectable hepatocellular carcinoma…

Thérapies de Conversion

Cui, K., Li, Z., Zhong, J., Shi, X., Zhao, L., Li, H., & Ma, Y. (2024). Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report.. Front Oncol, 14, 1355798. https://doi.org/10.3389/fonc.2024.1355798

01/01/2024 Lire →

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.

BACKGROUND: Hepatic artery infusion chemotherapy (HAI) has been proposed as a valuable adjunct for multimodal therapy of primary and secondary liver malignancies. This review provides an overview of t…

Thérapies de Conversion

Kuemmerli, C., Hess, V., Dutkowski, P., Sinz, S., Kessler, U., Hess, G. F., Billeter, A. T., Müller-Stich, B. P., Kollmar, O., & Müller, P. C. (2024). Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.. Pharmacology, 109(2), 86-97. https://doi.org/10.1159/000537887

01/01/2024 Lire →

Pathways to Care for Adolescents Attending a First Hormone Appointment at Canadian Gender Affirming Medical Clinics: A Cross-Sectional Analysis From the Trans Youth CAN! Study.

PURPOSE: Limited research has examined adolescents' pathways to gender-affirming medical care.METHODS: Enrollment in Trans Youth CAN! was at an initial appointment for hormone suppression or gender-af…

Thérapies de Conversion

Lawson, M. L., Gotovac, S., Couch, B., Gale, L., Vandermorris, A., Ghosh, S., & Bauer, G. R. (2024). Pathways to Care for Adolescents Attending a First Hormone Appointment at Canadian Gender Affirming Medical Clinics: A Cross-Sectional Analysis From the Trans Youth CAN! Study.. J Adolesc Health, 74(1), 140-147. https://doi.org/10.1016/j.jadohealth.2023.07.021

01/01/2024 Lire →